This site is intended for healthcare professionals

Incyte announces positive results from phase III TRuE-V program evaluating ruxolitinib cream in patients with vitiligo.

Read time: 1 mins
Last updated:28th Jun 2021
Published:21st May 2021
Incyte announced positive topline results from its pivotal Phase III TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age greater than 12 years) with vitiligo.
Condition: Vitiligo
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest